A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure
Phase of Trial: Phase IV
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms UPWARD
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 30 Apr 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 15 Jan 2019 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.
- 09 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.